RT Journal Article
SR Electronic
T1 Rare Variants in Pharmacogenes Influence Clozapine Metabolism in Individuals with Schizophrenia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.13.23287157
DO 10.1101/2023.03.13.23287157
A1 Kappel, Djenifer B.
A1 Rees, Elliott
A1 Fenner, Eilidh
A1 King, Adrian
A1 Jansen, John
A1 Helthuis, Marinka
A1 Owen, Michael J.
A1 O’Donovan, Michael C.
A1 Walters, James T.R.
A1 Pardiñas, Antonio F.
YR 2023
UL http://medrxiv.org/content/early/2023/03/17/2023.03.13.23287157.abstract
AB Clozapine is the only licensed medication for treatment-resistant schizophrenia (TRS). Few predictors for variation in response to clozapine have been identified, but clozapine metabolism is known to influence therapeutic response and the occurrence of adverse side effects. Here, we expand on genome-wide studies of clozapine metabolism, previously focused on common genetic variation, by analysing whole-exome sequencing data from 2062 individuals with schizophrenia taking clozapine in the UK. Our main aim is to investigate whether rare genomic variation in genes and gene sets involved in the clozapine metabolism pathway influences plasma concentrations of clozapine metabolites, assessed through the longitudinal analysis of 6585 pharmacokinetic assays. We observed a statistically significant association between the burden of rare damaging coding variants (MAF ≤1%) in gene sets broadly related to drug pharmacokinetics and lower clozapine (β= -0.054, SE= 0.019, P-value= 0.005) concentrations in plasma. We estimate that the effects in clozapine plasma concentrations of a single damaging allele in this gene set are akin to reducing the clozapine dose by about 35 mg/day. Gene-based analysis identified rare variants in CYP1A2, which encodes the enzyme responsible for converting clozapine to norclozapine, as having the strongest effects of any gene on clozapine metabolism (β= 0.324, SE= 0.124, P= 0.009). Our findings support the hypothesis that rare genetic variants in known drug-metabolising enzymes and transporters can markedly influence clozapine plasma concentrations. These results also converge with common variant evidence, particularly in relation to CYP1A2, suggesting the need for further evaluations of the pharmacogenomic makeup of this gene. Overall, our results suggest that pharmacogenomic efforts trying to predict clozapine metabolism and personalise drug therapy could benefit from the inclusion of rare damaging variants in pharmacogenes beyond those already identified and catalogued as PGx star alleles.Competing Interest StatementAK is a full-time employee of Magna Laboratories Ltd. MH and JJ are full-time employees of Leyden Delta B.V. MJO, MCOD, and JTRW are supported by a collaborative research grant from Takeda Pharmaceuticals Ltd. for a project unrelated to work presented here. ER, AP, MJO, MCOD, and JTRW also reported receiving grants from Akrivia Health for a project unrelated to this submission. Takeda and Akrivia played no part in the conception, design, implementation, or interpretation of this study.Funding StatementDBK and AFP were supported by the Academy of Medical Sciences Springboard award (SBF005\1083). The CLOZUK study was supported by grants from the Medical Research Council to Cardiff University: Centre (MR/L010305/1), Program (MR/P005748/1), and Project (MR/L011794/1, MC_PC_17212); as well as the European Union's Seventh Framework program (279227, CRESTAR). ER is supported by a UKRI Future Leaders Fellowship Grant (MR/T018712/1). EF is funded by a Wellcome Trust Integrative Neuroscience PhD Studentship. We also acknowledge the support of the Supercomputing Wales project, partly funded by the European Regional Development Fund (ERDF) via the Welsh Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The CLOZUK2 study received UK National Research Ethics Service approval (ref. 10/WSE02/15) in accordance with the UK Human Tissue Act.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesTo comply with the ethical and regulatory framework of the CLOZUK project, access to individual-level data requires a collaboration agreement with Cardiff University. Requests to access deidentified datasets, data dictionaries, and other summaries from the CLOZUK project should be directed to James T R Walters (waltersjt{at}cardiff.ac.uk).